Trials / Unknown
UnknownNCT04412174
A Study of GC022F CAR-T Cell Immunotherapy for Relapsed or Refractory B- NHL
- Status
- Unknown
- Phase
- EARLY_Phase 1
- Study type
- Interventional
- Enrollment
- 18 (estimated)
- Sponsor
- Hebei Yanda Ludaopei Hospital · Academic / Other
- Sex
- All
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
The study is an early, open, single-centered trial. The aim of this study is to evaluate the safety and tolerance of GC022F CAR-T cell immunotherapy in relapsed or refractory B-NHL. The investigators plan to include 18 subjects to receive GC022F therapy.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | GC022F | GC022F is a bispecific CAR-T cell immunotherapy that targeted CD19 and CD22. The dosage ranges from 3×10\^5 to 1×10\^6 CAR+T/Kg. |
Timeline
- Start date
- 2020-06-01
- Primary completion
- 2022-12-01
- Completion
- 2022-12-01
- First posted
- 2020-06-02
- Last updated
- 2020-06-02
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT04412174. Inclusion in this directory is not an endorsement.